Inc, AqueSys , a medical device company that develops, manufactures and markets XEN Gel Stent technology for the treatment of glaucoma internationally, today announced that it has secured $43. Series D funding of 6 million The round was led by a new undisclosed investor with the participation of existing investors Accuitive Medical Ventures, Carlyle Group, Longitude Capital, Rho Ventures and SV Life Sciences.
AqueSys also announced that it had successfully completed the enrollment of its first FDA IDE study and began the enrollment of its second FDA approved IDE study using an additional XEN Gel Stent model. In addition, the company has also recently launched a targeted international commercialisation
‘AqueSys is very pleased to raise this significant round of financing with a leading group of venture capital and private equity partners who share our vision to significantly improve the paradigm of glaucoma treatment through highly effective, yet minimally invasive technology. Our XEN Gel Stent international studies have demonstrated the minimally invasive ability of the technology to safely and significantly reduce intraocular pressure through the globally accepted gold standard mechanism of action (subconjunctival drainage) Our strong capitalization allows us to look forward confidently and accelerate the implementation and achievement of our clinical, regulatory and commercial objectives,” said Ron Bache, AqueSys, Inc. Chairman and Chief Executive Officer
Glaucoma is the number two cause of blindness affecting more than 60 million people worldwide. It is estimated to be a $5 billion annual market
AqueSys, Inc is a privately owned company headquartered in Orange County, California. The company focuses on the development, manufacture and commercialization of XEN Gel Stent technology used to treat vision-threatening patients with glaucoma.
www www Aquesis Come on,
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/AqueSys/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at email@example.com